Misyo (Methadone Hydrochloride)

Methadone Hydrochloride, the active ingredient in Misyo, is an opioid agonist presented as an oral formulation for oral use. It is employed to manage opioid dependence and to provide analgesia for moderate to severe pain in adult patients, helping to reduce withdrawal symptoms and control chronic pain when other treatments are insufficient.

GNH USA supplies Misyo as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide, with a focus on reliable quality and regulatory compliance and timely delivery.

Methadone Hydrochloride is used in the management of opioid‑related conditions and pain.

- Opioid dependence: reduces cravings and withdrawal symptoms, facilitating maintenance therapy. - Moderate to severe pain: provides analgesia when other opioids are inadequate. - Opioid withdrawal: alleviates acute withdrawal signs during detoxification.

Methadone Hydrochloride may cause a range of adverse reactions, varying from mild to severe.

Common Side Effects: - Constipation: reduced gastrointestinal motility. - Nausea: feeling of sickness. - Drowsiness: increased sleepiness. - Dry mouth: reduced salivation.

Serious or Rare Side Effects: - Respiratory depression: slowed breathing that can be life‑threatening. - QT interval prolongation: cardiac rhythm disturbance that may lead to arrhythmia. - Severe hypotension: marked drop in blood pressure.

When prescribing Methadone Hydrochloride, clinicians should observe several safety considerations.

- Cardiac assessment: evaluate QT interval and correct electrolyte imbalances. - Respiratory monitoring: watch for signs of depression, especially during initiation. - Hepatic function: adjust dosing in patients with liver impairment. - Concomitant CNS depressants: avoid or use with caution to prevent additive effects. - Pregnancy and lactation: weigh benefits against potential risks before use. - Store at room temperature: keep in the original container, protect from moisture and light.

Methadone Hydrochloride has notable drug interactions that may require dose adjustment or avoidance.

Major Interactions (Avoid): - Central nervous system depressants: combined use can cause profound respiratory depression. - Monoamine oxidase inhibitors: may precipitate serotonin syndrome. - QT‑prolonging agents: increase risk of cardiac arrhythmias.

Moderate Interactions (Monitor Closely): - CYP3A4 inhibitors (e.g., ketoconazole): raise methadone levels, requiring monitoring. - Selective serotonin reuptake inhibitors: may enhance serotonergic effects. - Antihistamines: can add to sedation and dizziness.